Intra-patient variability in tacrolimus exposure: Causes, consequences for clinical management

Transplantation Reviews

Volumn 29, Issue 2, 2015, Pages 78-84

  Shuker, Nauras ^a   Van Gelder, Teun ^a   Hesselink, Dennis A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; DIARRHEA; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MONITORING; FOOD DRUG INTERACTION; GRAFT REJECTION; HEREDITY; HUMAN; KIDNEY TRANSPLANTATION; NONHUMAN; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; QUANTITATIVE ANALYSIS; REVIEW; RISK FACTOR; TREATMENT REFUSAL; ADVERSE EFFECTS; METABOLISM;

DRUG MONITORING; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; TACROLIMUS;

EID: 84928209270     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2015.01.002     Document Type: Review

References (84)

1. Matas A.J., Smith J.M., Skeans M.A., et al. OPTN/SRTR 2011 annual data report: kidney. Am J Transplant 2013, 13:11-46.
2. Lamb K.E., Lodhi S., Meier-Kriesche H.U. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011, 11:450-462.
3. Nankivell B.J., Kuypers D.R. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011, 378:1428-1437.
4. Jardine A.G., Gaston R.S., Fellstrom B.C., Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet 2011, 378:1419-1427.
5. Farrugia D., Mahboob S., Cheshire J., et al. Malignancy-related mortality following kidney transplantation is common. Kidney Int 2014, 85:1395-1403.
6. van Gelder T. Within-patient variability in immunosuppressive drug exposure as a predictor for poor outcome after transplantation. Kidney Int 2014, 85:1267-1268.
7. Staatz C.E., Tett S.E. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004, 43:623-653.
8. van Gelder T. Drug interactions with tacrolimus. Drug Saf 2002, 25:707-712.
9. Shuker N., Bouamar R., Weimar W., van Schaik R.H., van Gelder T., Hesselink D.A. ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation. Clin Chim Acta 2012, 413:1326-1337.
10. Hesselink D.A., Bouamar R., Elens L., van Schaik R.H., van Gelder T. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet 2014, 53:123-139.
11. Baraldo M., Furlanut M. Chronopharmacokinetics of ciclosporin and tacrolimus. Clin Pharmacokinet 2006, 45:775-788.
12. Tada H., Satoh S., Iinuma M., et al. Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection. J Clin Pharmacol 2003, 43:859-865.
13. Wallemacq P., Armstrong V.W., Brunet M., et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 2009, 31:139-152.
14. Sapir-Pichhadze R., Wang Y., Famure O., Li Y., Kim S.J. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. Kidney Int 2014, 85:1404-1411.
15. Hsiau M., Fernandez H.E., Gjertson D., Ettenger R.B., Tsai E.W. Monitoring nonadherence and acute rejection with variation in blood immunosuppressant levels in pediatric renal transplantation. Transplantation 2011, 92:918-922.
16. Stifft F., Stolk L.M., Undre N., van Hooff J.P., Christiaans M.H. Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. Transplantation 2014, 97:775-780.
17. van Hooff J., Van der Walt I., Kallmeyer J., et al. Pharmacokinetics in stable kidney transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations. Ther Drug Monit 2012, 34:46-52.
18. Wu M.J., Cheng C.Y., Chen C.H., et al. Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients. Transplantation 2011, 92:648-652.
19. Wehland M., Bauer S., Brakemeier S., et al. Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations. Pharmacogenet Genomics 2011, 21:179-184.
20. Prytula A.A., Bouts A.H., Mathot R.A., et al. Intra-patient variability in tacrolimus trough concentrations and renal function decline in pediatric renal transplant recipients. Pediatr Transplant 2012, 16:613-618.
21. Borra L.C., Roodnat J.I., Kal J.A., Mathot R.A., Weimar W., van Gelder T. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant 2010, 25:2757-2763.
22. Lemahieu W., Maes B., Verbeke K., Rutgeerts P., Geboes K., Vanrenterghem Y. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am J Transplant 2005, 5:1383-1391.
23. Armendariz Y., Garcia S., Lopez R.M., Pou L. Hematocrit influences immunoassay performance for the measurement of tacrolimus in whole blood. Ther Drug Monit 2005, 27:766-769.
24. Brown N.W., Gonde C.E., Adams J.E., Tredger J.M. Low hematocrit and serum albumin concentrations underlie the overestimation of tacrolimus concentrations by microparticle enzyme immunoassay versus liquid chromatography-tandem mass spectrometry. Clin Chem 2005, 51:586-592.
25. Cannon R.D., Wong S.H., Hariharan S., et al. Clinical efficacy of the Abbott Tacrolimus II assay for the IMx. Ann Clin Lab Sci 1999, 29:299-302.
26. Boer K., Deufel T., Schmidt D., Streck S., Kiehntopf M. Application of the EMIT 2000 tacrolimus assay on the Abbott Architect c8000 high volume clinical chemistry analyzer. Clin Biochem 2006, 39:1041-1043.
27. Ansermot N., Fathi M., Veuthey J.L., Desmeules J., Rudaz S., Hochstrasser D. Quantification of cyclosporine and tacrolimus in whole blood. Comparison of liquid chromatography-electrospray mass spectrometry with the enzyme multiplied immunoassay technique. Clin Biochem 2008, 41:910-913.
28. Koster R.A., Dijkers E.C., Uges D.R. Robust, high-throughput LC-MS/MS method for therapeutic drug monitoring of cyclosporine, tacrolimus, everolimus, and sirolimus in whole blood. Ther Drug Monit 2009, 31:116-125.
29. Michel M.C., Heemann U., Philipp T. Comparison of old and new IMX assays for monitoring of tacrolimus levels. Transpl Int 1997, 10:409-410.
30. Tredger J.M., Gilkes C.D., Gonde C.E. Therapeutic monitoring of tacrolimus (FK506) with the first- and second-generation microparticle enzyme immunoassays: performance and results in four patient populations. Ther Drug Monit 1998, 20:266-275.
31. Bekersky I., Dressler D., Mekki Q.A. Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J Clin Pharmacol 2001, 41:176-182.
32. Bekersky I., Dressler D., Mekki Q. Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol 2001, 41:289-297.
33. Kimikawa M., Kamoya K., Toma H., Teraoka S. Effective oral administration of tacrolimus in renal transplant recipients. Clin Transplant 2001, 15:324-329.
34. Liu C., Shang Y.F., Zhang X.F., et al. Co-administration of grapefruit juice increases bioavailability of tacrolimus in liver transplant patients: a prospective study. Eur J Clin Pharmacol 2009, 65:881-885.
35. Bailey D.G., Malcolm J., Arnold O., Spence J.D. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998, 46:101-110.
36. Uno T., Yasui-Furukori N. Effect of grapefruit juice in relation to human pharmacokinetic study. Curr Clin Pharmacol 2006, 1:157-161.
37. Egashira K., Fukuda E., Onga T., et al. Pomelo-induced increase in the blood level of tacrolimus in a renal transplant patient. Transplantation 2003, 75:1057.
38. Egashira K., Sasaki H., Higuchi H., Ieiri I. Food-drug interaction of tacrolimus with pomelo, ginger, and turmeric juice in rats. Drug Metab Pharmacokinet 2012, 27:242-247.
39. Zhang W., Tan T.M., Lim L.Y. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats. Drug Metab Dispos 2007, 35:110-115.
40. Zhang W., Lim L.Y. Effects of spice constituents on P-glycoprotein-mediated transport and CYP3A4-mediated metabolism in vitro. Drug Metab Dispos 2008, 36:1283-1290.
41. Zylber-Katz E., Granot E. Abrupt increase of tacrolimus blood levels during an episode of Shigella infection in a child after liver transplantation. Ther Drug Monit 2001, 23:647-649.
42. Fruhwirth M., Fischer H., Simma B., et al. Rotavirus infection as cause of tacrolimus elevation in solid-organ-transplanted children. Pediatr Transplant 2001, 5:88-92.
43. Fruhwirth M., Fischer H., Simma B., Ellemunter H. Elevated tacrolimus trough levels in association with mycophenolate mofetil-induced diarrhea: a case report. Pediatr Transplant 2001, 5:132-134.
44. Matsui A., Arakawa Y., Momoya T., Sasaki N., Kawasaki S., Tanaka K. Apparently increased trough levels of tacrolimus caused by acute infantile diarrhea in two infants with biliary atresia after liver transplantation. Acta Paediatr Jpn 1996, 38:699-701.
45. Hochleitner B.W., Bosmuller C., Nehoda H., et al. Increased tacrolimus levels during diarrhea. Transpl Int 2001, 14:230-233.
46. Eades S.K., Boineau F.G., Christensen M.L. Increased tacrolimus levels in a pediatric renal transplant patient attributed to chronic diarrhea. Pediatr Transplant 2000, 4:63-66.
47. Maes B.D., Lemahieu W., Kuypers D., et al. Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. Am J Transplant 2002, 2:989-992.
48. van Boekel G.A., Aarnoutse R.E., van der Heijden J.J., Hoogtanders K.E., Hilbrands L.B. Effect of mild diarrhea on tacrolimus exposure. Transplantation 2012, 94:763-767.
49. Watkins P.B. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 1997, 27:161-170.
50. Plosker G.L., Foster R.H. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000, 59:323-389.
51. Thorn M., Finnstrom N., Lundgren S., Rane A., Loof L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 2005, 60:54-60.
52. Christians U., Jacobsen W., Benet L.Z., Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002, 41:813-851.
53. van Maarseveen E.M., Rogers C.C., Trofe-Clark J., van Zuilen A.D., Mudrikova T. Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review. AIDS Patient Care STDS 2012, 26:568-581.
54. Hesselink D.A., Ngyuen H., Wabbijn M., et al. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. Br J Clin Pharmacol 2003, 56:327-330.
55. van Maarseveen E.M., Crommelin H.A., Mudrikova T., van den Broek M.P., van Zuilen A.D. Pretransplantation pharmacokinetic curves of tacrolimus in HIV-infected patients on ritonavir-containing cART: a pilot study. Transplantation 2013, 95:397-402.
56. Hu Z., Yang X., Ho P.C., et al. Herb-drug interactions: a literature review. Drugs 2005, 65:1239-1282.
57. Mannel M. Drug interactions with St John's wort: mechanisms and clinical implications. Drug Saf 2004, 27:773-797.
58. Moore L.B., Goodwin B., Jones S.A., et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000, 97:7500-7502.
59. Mai I., Stormer E., Bauer S., Kruger H., Budde K., Roots I. Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 2003, 18:819-822.
60. van Gelder T., van Schaik R.H., Hesselink D.A. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation. Nat Rev Nephrol 2014, 10:725-731.
61. Staatz C.E., Goodman L.K., Tett S.E. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet 2010, 49:141-175.
62. Wang D., Guo Y., Wrighton S.A., Cooke G.E., Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 2011, 11:274-286.
63. Elens L., Bouamar R., Hesselink D.A., et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 2011, 57:1574-1583.
64. Chung J.Y., Lee Y.J., Jang S.B., Lim L.A., Park M.S., Kim K.H. CYP3A5*3 genotype associated with intrasubject pharmacokinetic variation toward tacrolimus in bioequivalence study. Ther Drug Monit 2010, 32:67-72.
65. Ro H., Min S.I., Yang J., et al. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation. Ther Drug Monit 2012, 34:680-685.
66. Pashaee N., Bouamar R., Hesselink D.A., et al. CYP3A5 genotype is not related to the intrapatient variability of tacrolimus clearance. Ther Drug Monit 2011, 33:369-371.
67. Spierings N., Holt D.W., MacPhee I.A. CYP3A5 genotype had no impact on intrapatient variability of tacrolimus clearance in renal transplant recipients. Ther Drug Monit 2013, 35:328-331.
68. Butler J.A., Roderick P., Mullee M., Mason J.C., Peveler R.C. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation 2004, 77:769-776.
69. van Gelder T., Gabardi S. Methods, strengths, weaknesses, and limitations of bioequivalence tests with special regard to immunosuppressive drugs. Transpl Int 2013, 26:771-777.
70. van Gelder T. European Society for Organ Transplantation Advisory Committee recommendations on generic substitution of immunosuppressive drugs. Transpl Int 2011, 24:1135-1141. E.A.C.o.G. Substitution.
71. Kahan B.D., Welsh M., Urbauer D.L., et al. Low intraindividual variability of cyclosporin A exposure reduces chronic rejection incidence and health care costs. J Am Soc Nephrol 2000, 11:1122-1131.
72. Kahan B.D., Welsh M., Schoenberg L., et al. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 1996, 62:599-606.
73. Stoves J., Newstead C.G. Variability of cyclosporine exposure and its relevance to chronic allograft nephropathy: a case-control study. Transplantation 2002, 74:1794-1797.
74. Waiser J., Slowinski T., Brinker-Paschke A., et al. Impact of the variability of cyclosporin A trough levels on long-term renal allograft function. Nephrol Dial Transplant 2002, 17:1310-1317.
75. Savoldi S., Maiorca R., Chiappini R., Scolari F., Sandrini S. Trough cyclosporine concentration variability. Transplant Proc 1998, 30:1642-1644.
76. Inoue S., Beck Y., Nagao T., Uchida H. Early fluctuation in cyclosporine A trough levels affects long-term outcome of kidney transplants. Transplant Proc 1994, 26:2571-2573.
77. Pollock-Barziv S.M., Finkelstein Y., Manlhiot C., et al. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children. Pediatr Transplant 2010, 14:968-975.
78. De Bleser L., Matteson M., Dobbels F., Russell C., de Geest S. Interventions to improve medication-adherence after transplantation: a systematic review. Transpl Int 2009, 22:780-797.
79. Tielen M., van Exel J., Laging M., et al. Attitudes to medication after kidney transplantation and their association with medication adherence and graft survival: a 2-year follow-up study. J Transplant 2014, 2014:9. [675301].
80. Tielen M., van Staa A.L., Jedeloo S., van Exel N.J., Weimar W. Q-methodology to identify young adult renal transplant recipients at risk for nonadherence. Transplantation 2008, 85:700-706.
81. Hougardy J.M., de Jonge H., Kuypers D., Abramowicz D. The once-daily formulation of tacrolimus: a step forward in kidney transplantation?. Transplantation 2012, 93:241-243.
82. Kuypers D.R., Peeters P.C., Sennesael J.J., et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation 2013, 95:333-340.
83. Shuker N., Cadogan M., van Gelder T., et al. Conversion from twice-daily to once-daily tacrolimus does not reduce intra-patient variability in tacrolimus exposure. Ther Drug Monit 2014.
84. Bunnapradist S., Ciechanowski K., West-Thielke P., et al. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. Am J Transplant 2013, 13:760-769.